| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2014 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aclaris Therapeutics, Inc. | 5 | Q4 2017 | 35.0% |
| Spark Therapeutics, Inc. | 5 | Q4 2017 | 26.2% |
| Natera, Inc. | 5 | Q4 2017 | 12.2% |
| Auris Medical Holding AG | 5 | Q4 2017 | 3.9% |
| Histogenics Corporation | 5 | Q4 2017 | 2.5% |
| ObsEva SA | 4 | Q4 2017 | 25.3% |
| Versartis, Inc. | 3 | Q2 2017 | 19.8% |
| Mirna Therapeutics, Inc. | 3 | Q2 2017 | 3.4% |
| Innocoll Holdings PLC | 3 | Q2 2017 | 2.7% |
| NuCana plc | 2 | Q4 2017 | 25.8% |
View Sofinnova Management VIII, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-09-20 |
| 3 | 2018-09-13 |
| 13F-HR | 2018-02-14 |
| 13F-HR | 2017-10-11 |
| 13F-HR | 2017-07-19 |
| 13F-HR | 2017-04-10 |
| 13F-HR | 2017-02-14 |
| 4 | 2015-10-13 |
| 3 | 2015-10-06 |
| 4 | 2015-10-06 |
View Sofinnova Management VIII, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.